JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospective Randomized Study
Phiphatpatthamaamphan, Kittichet; Vilaichone, Ratha-korn; Siramolpiwat, Sith; Tangaroonsanti, Anupong; Chonprasertsuk, Soonthorn; Bhanthumkomol, Patommatat; Pornthisarn, Bubpha; Mahachai, Varocha;
  PDF(new window)
 Abstract
Background: Studies of effects of IL-1 polymorphisms, CYP2C19 genotype together with antibiotic resistance for H. pylori eradication are rare worldwide. The present study was designed to evaluate efficacy of 10-day sequential therapy (SQT) and 14-day standard triple therapy (STT) with four- times-daily dosing of amoxicillin for H. pylori eradication related to these important host and bacterial factors in Thailand. Materials and Methods: This prospective randomized study was performed during March 2015 to January 2016. H. pylori infected gastritis patients were randomized to receive 10-day sequential therapy and 14-day standard triple therapy. CYP2C19 genotyping, IL1 polymorphism (IL-1B and IL-1RN genotypes) and antibiotic susceptibility tests were performed in all patients. 13C-UBT was conducted to confirm H. pylori eradication at least 4 weeks after treatment. Results: A total of 100 patients (33 males and 67 females, mean age
 Keywords
IL-1 polymorphisms;dosing scheme of amoxicillin triple therapy;10-day sequential therapy;
 Language
English
 Cited by
 References
1.
Chey WD, Wong BC (2007). American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol, 102, 1808-25. crossref(new window)

2.
Demirel BB, Akkas BE, Vural GU (2013). Clinical factors related with helicobacter pylori infection - is there an association with gastric cancer history in first- degree family members? Asian Pac J Cancer Prev, 14, 1797-1802. crossref(new window)

3.
Ford AC, Forman D, Hunt RH, et al (2014). Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ, 348, 3174. crossref(new window)

4.
Furuta T, Shirai N, Takashima M, et al (2001). Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther, 69, 158-68. crossref(new window)

5.
Furuta T, Sugimoto M, Yamade M, et al (2014). Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol, 54, 258-66. crossref(new window)

6.
Gatta L, Vakil N, Leandro G, et al (2009). Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol, 104, 3069–79. crossref(new window)

7.
Graham DY (2009). Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol, 7, 145-8. crossref(new window)

8.
Jafri NS, Hornung CA, Howden CW, (2008). Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med, 148, 923-31. crossref(new window)

9.
Jainan W, Vilaichone RK (2014). Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer. Asian Pac J Cancer Prev, 15, 10957-60

10.
Mahachai V, Sirimontaporn N, Tumwasorn S, et al (2011). Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test. J Gastroenterol Hepatol, 26, 825-8. crossref(new window)

11.
Malfertheiner P, Megraud F, O’Morain CA, et al (2012). Management of Helicobacter pylori infection--the maastricht iv/ florence consensus report. Gut, 61, 646-64. crossref(new window)

12.
Prapitpaiboon H, Mahachai V, Vilaichone RK (2015). High efficacy of levofloxacin-dexlansoprazole-based quadruple therapy as a first line treatment for Helicobacter pylori eradication in Thailand. Asian Pac J Cancer Prev, 16, 4353-6. crossref(new window)

13.
Sirimontaporn N, Thong-Ngam D, Tumwasorn S, et al (2010). Ten-day sequential therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol, 105, 1071–5. crossref(new window)

14.
Srinarong C, Siramolpiwat S, Wongcha-um A, et al (2014). Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. Asian Pac J Cancer Prev, 15, 9909-13. crossref(new window)

15.
Vilaichone RK, Gumnarai P, Ratanachu-Ek T, et al (2013). Nationwide survey of Helicobacter pylori antibiotic resistance in Thailand. Diagn Microbiol Infect Dis, 77, 346-9. crossref(new window)

16.
Vilaichone RK, Mahachai V (2001). Current management of Helicobacter pylori infection. J Med Assoc Thai, 84, 32-38.

17.
Vilaichone RK, Mahachai V, Tumwasorn S, et al (2005). Gastric mucosal cytokine levels in relation to host interleukin-1 polymorphisms and Helicobacter pylori cagA genotype. Scand J Gastroenterol, 40, 530-39

18.
Vilaichone RK, Mahachai V, Graham DY (2006). Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am, 35, 229-47. crossref(new window)

19.
Vilaichone RK, Prapitpaiboon H, Gamnarai P, et al (2015). Seven-day bismuth-based quadruple therapy as an initial treatment for Helicobacter pylori infection in a high metronidazole resistant area. Asian Pac J Cancer Prev, 16, 6089-6092. crossref(new window)

20.
Yamada S, Onda M, Kato S, et al (2001). Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol, 36, 669-72. crossref(new window)

21.
Zullo A, De Francesco V, Hassan C, et al (2007). The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut, 56, 1353-7. crossref(new window)